Cardiovascular Systems Inc (NASDAQ:CSII) General Counsel Alexander Rosenstein sold 1,136 shares of the business’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $47.04, for a total transaction of $53,437.44. Following the completion of the sale, the general counsel now directly owns 79,589 shares of the company’s stock, valued at approximately $3,743,866.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of CSII stock opened at $50.81 on Thursday. The company’s 50-day moving average price is $45.48 and its 200-day moving average price is $39.87. The company has a current ratio of 4.25, a quick ratio of 3.83 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -5,081.00 and a beta of 1.77. Cardiovascular Systems Inc has a twelve month low of $24.84 and a twelve month high of $51.74.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings results on Tuesday, August 6th. The medical device company reported $0.04 earnings per share for the quarter, meeting the consensus estimate of $0.04. The firm had revenue of $68.23 million for the quarter, compared to analysts’ expectations of $66.04 million. Cardiovascular Systems had a negative net margin of 0.10% and a negative return on equity of 0.18%. As a group, equities research analysts predict that Cardiovascular Systems Inc will post 0.02 EPS for the current year.
Several brokerages recently commented on CSII. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, August 7th. Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “strong sell” rating and set a $47.00 target price for the company. in a report on Thursday, August 8th. Lake Street Capital upped their target price on shares of Cardiovascular Systems from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. BidaskClub raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Saturday, August 17th. Finally, Stifel Nicolaus lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating and upped their target price for the stock from $41.00 to $45.00 in a report on Tuesday, July 16th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $48.50.
Hedge funds have recently made changes to their positions in the company. Stonebridge Capital Advisors LLC acquired a new position in shares of Cardiovascular Systems during the 2nd quarter valued at about $26,000. Altshuler Shaham Ltd acquired a new position in shares of Cardiovascular Systems during the 2nd quarter valued at about $28,000. Advisor Group Inc. boosted its position in shares of Cardiovascular Systems by 88.8% during the 2nd quarter. Advisor Group Inc. now owns 655 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 308 shares during the last quarter. Personal Wealth Partners acquired a new position in shares of Cardiovascular Systems during the 2nd quarter valued at about $78,000. Finally, Pearl River Capital LLC acquired a new position in shares of Cardiovascular Systems during the 1st quarter valued at about $98,000. 94.33% of the stock is currently owned by hedge funds and other institutional investors.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
See Also: Day Trading
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.